145106-46-3Relevant academic research and scientific papers
INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7)
-
, (2019/08/08)
The present invention provides, inter alia, compounds having the structures of formulas described herein; pharmaceutically acceptable salts, solvates, hydrates, tautomers, and isotopic forms thereof; and compositions (e.g., pharmaceutical compositions and kits) containing one or more of the foregoing. Also provided are methods of administering and uses involving the compounds and/or pharmaceutical compositions for treating or preventing disease. The disease can be a proliferative disease, such as a cancer (e.g., a blood cancer (e.g., a leukemia or lymphoma), a brain cancer, a breast cancer, melanoma, multiple myeloma, or an ovarian cancer) a benign neoplasm, pathologic angiogenesis, or a fibrotic disease. While no aspect of the invention is limited by the biological events that may transpire, administering a compound or other composition described herein may selectively inhibit the aberrant expression or activity of cyclin-dependent kinase 7 (CDK7) and, thereby, induce cellular apoptosis and/or inhibit the transcription of disease-related genes in the patient (or in a biological sample).
COMPOUNDS, COMPOSITIONS AND METHODS FOR SYNTHESIS
-
Paragraph 00787; 00788; 00791; 00792, (2019/01/10)
The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.
SELECTIVE ANDROGEN RECEPTOR MODULATORS
-
Page/Page column 33-34, (2013/04/25)
The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.
Kinetic resolution of amino alcohol derivatives with a chiral nucleophilic catalyst: Access to enantiopure cyclic cis-amino alcohols
Kawabata,Yamamoto,Momose,Yoshida,Nagaoka,Fuji
, p. 2700 - 2701 (2007/10/03)
Acylative kinetic resolution of racemic cyclic cis-amino alcohol derivatives with a chiral nucleophilic catalyst proceeds enantioselectively (s = 10-21) at ambient temperature to give enantiopure recovered materials, and the % conversion of the acylation can be readily controlled by the amount of acid anhydride.
Amino acid derived thiane oxide and dioxide systems as disposable templates: Synthesis of α-amino ketones, anti-amino alcohols and an amino cyclopentenone
Gamble, Mark P.,Giblin, Gerard M. P.,Montana, John G.,O'Brien, Peter,Ockendon, Timothy P.,Taylor, Richard J. K.
, p. 7457 - 7460 (2007/10/03)
Sulfones and sulfoxides synthesised from methionine and homocysteine thiolactone have been cyclised to amino ketones using potassium bis(trimethylsilyl)amide. Ramberg-Backlund chemistry on one of the sulfones gave an amino cyclopentenone whereas acyclic α-amino ketones and anti-amino alcohols were obtained by Raney nickel desulfurisation of the sulfoxides.
Synthesis of enantiopure N-tert-butoxycarbonyl-2-aminocycloalkanones
Aube,Wolfe,Yantiss,Cook,Takusagawa
, p. 3003 - 3012 (2007/10/02)
A route to enantiomerically pure N-tert-butoxycarbonyl-2-aminocycloalkanones (ring size: 5-8 membered) from the corresponding cycloalkene oxides is described. The procedure involves (1) aminolysis with (S)-α-methylbenzylamine/Me3Al and chromatographic separation of diastereomers, (2) hydrogenolysis to afford the trans-2-aminocycloalkanols, (3) tert-butoxycarbonyl (Boc) protection, and (4) PCC oxidation.
